Biocon Limited
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
23
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 4, 2026The maintenance fee for Methods for controlling fucosylation levels in proteins (US 10,308,970) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
- 2 fees due Jan 14 to 28, 2027 · next Jan 14
- 3 fees due Feb 11 to 20, 2027 · next Feb 11
- 1 fee due Apr 29, 2027The maintenance fee for Crystalline Forms of Posaconazole Intermediate and Process for the Preparation of Amorphous Posaconazole (US 10,457,668) comes due Apr 29, 2027. Unpaid by Oct 29, 2027, it lapses early.
- 1 fee due Jun 22, 2027The maintenance fee for Monoclonal Antibody and a Method Thereof (US 9,217,037) comes due Jun 22, 2027. Unpaid by Dec 22, 2027, it lapses early.
- 2 fees due Jul 7 to 26, 2027 · next Jul 7
- 1 fee due Aug 9, 2027The maintenance fee for Fermentation medias and processes thereof (US 9,255,285) comes due Aug 9, 2027. Unpaid by Feb 9, 2028, it lapses early.
Recent changes
- 2 terms have ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,329,958 | Combinatorial synthesis of PEG oligomer libraries In force · From the USPTO record | In force | From the USPTO record | |
| US 8,563,685 | Fatty acid formulations and oral delivery of proteins and peptides, and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,058,391 | Process for the preparation of insulin conjugate IN-105 In force · From the USPTO record | In force | From the USPTO record | |
| US 7,872,095 | Insulin-oligomer conjugates, formulations and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 7,875,700 | Cation complexes of insulin compound conjugates, formulation and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 7,932,366 | Synthesis of azo bonded immunoregulatory compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 9,101,596 | Cation complexes of insulin compound conjugates, formulations and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,802,816 | Method of obtaining a purified, biologically active heterologous protein In force · From the USPTO record | In force | From the USPTO record | |
| US 9,102,758 | Insulin-oligomer conjugates, formulations and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,670,285 | Monoclonal Antibody and a Method Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 65: 1 patent in force now held by others · 50 lapsed for an unpaid fee · 46 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
9 pending · 6 abandoned · 15 no status recorded